Article info

Download PDFPDF
High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature

Authors

  • M. BAUR Applied Cancer Research—Institution for Translational Research Vienna, (ACR-ITR VIEnna)3rd Medical Department—Centre for Oncology and Haematology, Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital PubMed articlesGoogle scholar articles
  • B. FAZENY-DOERNER Department of Internal Medicine I, University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • S. J. OLSEN Department of Human Pharmacology, Bristol-Myers Squibb—Pharmaceutical Research Institute (BMS-PRI), Princeton, New Jersey PubMed articlesGoogle scholar articles
  • C. DITTRICH Applied Cancer Research—Institution for Translational Research Vienna, (ACR-ITR VIEnna)3rd Medical Department—Centre for Oncology and Haematology, Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to: Christian Dittrich, MD, Ludwig Boltzmann-Institute for Applied Cancer Research, 3rd Medical Department—Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Kundratstrasse 3, A-1100 Vienna, Austria. Email: christian.dittrich{at}wienkav.at

Citation

BAUR M, FAZENY-DOERNER B, OLSEN SJ, et al
High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature

Publication history

  • First published May 1, 2008.
Online issue publication 
May 01, 2008

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.